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Viewpoint
Providing answers to 
respiratory patients’ questions 
during COVID-19
The European Lung Foundation (ELF) brings 
patients and the public together with respiratory 
professionals to positively influence lung health, and 
regularly provides reliable information that has been 
co-produced by patients and professionals (from the 
European Respiratory Society (ERS)) and is available 
in multiple languages.
COVID-19
The ELF team closely monitored the first reports 
of the novel coronavirus in China and first wrote 
an article on 27 January 2020. This was quickly 
followed up by a page on the ELF website with the 
basic facts and figures that were taken primarily 
from the World Health Organization (WHO).
It was clear that this disease would be of concern 
to respiratory patients and it was agreed that a 
system should be put in place where patients 
could ask questions and have these answered by 
an expert.
Developing the resources
Initially an email was sent out to the patient 
organisations that are part of the ELF network [1] 
to ask if they were aware of questions that patients 
had. In parallel, the ELF team started to collate 
questions that they thought may be important 
for respiratory patients. On 3 March 2020, ELF 
contacted Professor James Chalmers, an ERS expert 
in infectious diseases, to ask whether he would be 
willing to answer a few of our enquires so they could 
be added as a question and answer (Q&A) section 
on the website; he agreed.
After publishing the first Q&A, questions started 
to flood into our inbox. Between 6 March 2020 
and 19 June 2020 we received 875 questions. The 
team were unable to answer these all directly, so 
an automated response was set-up to acknowledge 
receipt and direct them to the Q&A where their 
questions would be covered. Questions had their 
personal identifiers and specific information 
removed to leave the core question: e.g. “I have 
bronchiectasis, am I at higher risk if I catch COVID-
19?”. These were then sent to Prof. Chalmers and 
posted onto the ELF website in the form of a Q&A, 
which was updated weekly.
Concurrently, some ERS members got in touch 
with ELF to ask whether we had a resource for them 
to signpost patients to as they did not have the 
capacity to respond directly. They too used the Q&A 
for this purpose.
The challenges
With a small ELF team, February, March and April 
were challenging, but rewarding. The process of 
developing the Q&A with Prof. Chalmers and other 
ERS experts in specific areas helped the team 
understand the issues that patients were concerned 
about, and allowed them to keep up-to-date and 
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informed about the information that was available. 
There was a real worry that patients had no one 
to turn to during this period, and the need for 
evidence-based information was evident.
Rapidly developing situation
Answering questions about COVID-19, especially 
in the early stages, was difficult as there were 
often no clear answers. The lack of clarity for the 
public and people living with lung conditions led 
to increased anxiety about the disease, which was 
evident in the types of questions that were being 
asked. As more information was gathered, the 
advice evolved and changed on a regular basis. 
This made it difficult to keep the website up-to-
date and some information could not be posted 
as it evolved too rapidly to provide a useful picture 
for the public.
Different situations in 
different countries
The questions received by ELF came from many 
countries and continents, which meant that the 
challenges and government guidance were often 
different. The answers were checked to ensure that 
they could apply to all of Europe.
Need for different languages
ELF produces materials in nine core languages, 
but factsheets in up to 22 languages. The COVID-
19 Q&A needed to be in as many languages as 
possible, but there were budgetary constraints. 11 
languages were chosen: English, French, German, 
Italian, Spanish, Polish, Russian, Greek, Portuguese, 
Turkish and Persian. These included core languages 
and languages that volunteers came forward to help 
with. The translations were processed and uploaded 
weekly.
Making it visible
ELF promoted the Q&A through its newsletter, email 
lists and social media. It was also included as part of 
the ERS COVID-19 resource centre and promoted 
in the ERS newsletter. The total number of unique 
visits to the ELF website from 1 March to 13 July 
2020 was 852 194 compared with 464 594 in the 
same period the previous year. 308 696 of these 
sessions were driven by the COVID-19 Q&A.
The evolution of COVID-19
What has been interesting has been the evolution of 
the questions and where the questions have been 
coming from over the course of COVID-19.
The questions asked
Initially the questions were more generalised and 
either focused on the disease, or the increased 
risk that underlying lung conditions might pose, 
for example: “I have sarcoidosis, am I more at risk 
of severe illness if I catch COVID-19?” or “I have 
asthma, am I more at risk of catching COVID-19?”.
People were fearful that they would die of the 
disease and directly asked if this would be the case. 
There were concerns about shortages of ventilators 
and whether having a pre-existing condition would 
mean that a “healthy” person would be prioritised 
over them.
Fears arose from stories in the media, e.g. people 
with asthma fearing their steroid inhaler might 
make them more susceptible to the disease. Some 
were altruistic and asked whether their noninvasive 
ventilation equipment could be adapted and used 
for ventilation for others.
As time moved on, and more people had 
contracted COVID-19, the questions evolved to 
concerns about family members who had the 
disease and whether they would recover or whether 
the symptoms a person was experiencing could be 
COVID-19.
Along with questions about the long-term health 
effects of COVID-19, some people asked questions 
about symptoms that they were experiencing months 
after having the disease. As lockdowns eased, the 
questions became more focused on local guidelines, 
wearing masks in public spaces, shielding and how 
people who are vulnerable can start return to work.
The places the questions 
came from
We have seen geographical variance throughout the 
pandemic, initially most questions were from native 
English-speaking countries, as were visitors to the 
ELF website pages. As the questions were translated 
and there was increased awareness, the visitors to 
the COVID-19 pages diversified. In total, people from 
227 countries and territories have visited the website 
over the course of the pandemic; the top 20 of which 
can be seen in figure 1. The countries with the largest 
number of visitors were the UK and the USA with 
92 735 and 45 170 users, respectively, for this period.
As the visitors from other countries increased, 
so did the questions. Once the first wave in Europe 
had subsided, Mexico became the country with 
the fastest growing number of visitors, along with 
peaks from Argentina, Venezuela and Ecuador. 
This increase in access from South and Central 
America coincided with a peak in the questions 
being received from these areas.
Other resources
ELF produced a range of resources over the course 
of the pandemic, including the ability to share 
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experiences and stories, lay reviews of the latest 
scientific papers in the field, videos from experts 
answering specific questions about the pandemic, 
and factsheets on a range of issues (including what 
to expect if you are hospitalised and looking after 
your mental wellbeing) [2].
Many national and pan-European groups have 
also developed fantastic COVID-19 materials, and 
we have tried to act as a hub for these materials 
and for surveys and other activities being carried 
out over the course of this pandemic.
Conclusion
At the time of writing (August 2020), it is clear that 
many questions need to be answered about what 
the long-term impact of COVID-19 is. Are COVID-
19 patients going to develop long-term respiratory 
conditions? Will rehabilitation be required? Will 
global lung function levels be impacted? Why are 
different groups more adversely affected? When will 
there be a vaccine, and will it be safe for respiratory 
patients?
It is clear from the success of this ELF initiative 
that patients and the public value access to reliable 
information, and particularly value the interactive 
nature of the Q&A format. These resources 
need to respond to the needs of those wanting 
answers and need to consider different aspects, 
such as the ever-changing status of information 
available and maintaining public confidence and 
managing concerns while dealing with rapidly 
evolving information. It is also vital to be able to 
offer resources in different languages.
For ELF, this has been an opportunity to work 
closely with the public, patients and patient 
organisations across Europe, and with healthcare 
professionals on the front line of the pandemic. 
The partnership between ERS and ELF has proved 
invaluable during this time.
We have learned valuable lessons during the 
pandemic which will inform future approaches to 
supporting respiratory patients.
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Figure  1 Two line charts displaying the countries with the highest numbers of users of the ELF 
Q&A webpage (the UK and USA have been removed to show the other countries in more detail) 
in the period 1 March–13 July 2020: a) countries ranked 3–11; b) countries ranked 11–20.
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